Tscan Therapeutics Inc
TCRX
Get informed when a big investor buys or sells
+ FollowMarket Cap$47.56M
Close$
$-1.58
304.4% downside
Current Fair Value
304.4% downsideOvervalued by 304.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $47.56 Million |
|---|---|
| Enterprise Value | $38.89 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1 |
| Beta | 1.07 |
| Outstanding Shares | 129,948,878 |
Return
| Return on Equity | -170.55% |
|---|---|
| Return on Assets | -68.66% |
| Return on Invested Capital | -84.76% |
Valuation & Multiples
| P/E Ratio | -0.86 |
|---|---|
| PEG | 4.8 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 8.45 |
| Enterprise Value to EBIT | -0.33 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 2.35 |
| Debt to Equity | 1.33 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 12, 2026
EPS Estimate
$-0.25
Average shareholder expectationRevenue Estimate
$1.88 M
Average shareholder expectationNext Earnings Call
Expected Date
August 19, 2026
EPS Estimate
$-0.26
Average shareholder expectationRevenue Estimate
$1.88 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 24.99%▲ 1.36% |
|---|---|
| Total Invested | $32.78M▲ 6.81% |
| Investors Holding | 58▼ 2.00% |
ESG Score
No data
About Tscan Therapeutics Inc
61 employees